Like any pharmacologically active peptide-based therapy, it also comes with a side effect profile that patients and clinicians need to understand
These drugs work by reducing cravings or causing severe nausea when alcohol is consumed, but they are seldom prescribed for a variety of reasons
Starting BMI 37.3 @ADA_DiabetesPro @AmDiabetesAssn Up to 24% weight loss Attainment of weight reduction targets with retatrutide in P2 for PPL with #obesity #ADA2023 @AmDiabetesAssn @ADA_DiabetesPro And the summary of the P2 trial for retatrutide in PPL with #obesity #ADA2023 @AmDiabetesAssn @ADA_Pubs #weightloss The Glucagon-GIP-GLP-1R triple agonist Retatrutide P2 #Obesity Data #weightloss presented #ADA2023 @AmDiabetesAssn @ADA_DiabetesPro published online @NEJM Data for arrhythmias reported with the Glucagon-GIP-GLP-1RA Retatrutide in the P2 trial in PPL w #Obesity #ADA2023 #Heartdisease nejm.org/doi/suppl/10.1 Join the conversation
Failure to Warn Allegations Lawsuits against Novo Nordisk and Eli Lilly are built on allegations that both pharmaceutical companies failed to properly warn consumers about the health risks tied to their GLP-1 drugs
There were zero reports of AD-type dementia in the H2RA administration group, and the PPI administration group had 80 reports (Makunts et al
Beyond fill-finish services, validating packaging components with regulatory authorities can be a time-consuming process
